COMPASS Pathways (NASDAQ:CMPS) Given New $45.00 Price Target at HC Wainwright

COMPASS Pathways (NASDAQ:CMPS - Free Report) had its target price lowered by HC Wainwright from $60.00 to $45.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for COMPASS Pathways' FY2028 earnings at $0.14 EPS and FY2029 earnings at $1.63 EPS.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Maxim Group lowered their price objective on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways presently has an average rating of "Buy" and an average price target of $30.60.

COMPASS Pathways Stock Up 3.4 %

Shares of NASDAQ CMPS traded up $0.15 during mid-day trading on Thursday, reaching $4.57. The company had a trading volume of 1,307,053 shares, compared to its average volume of 1,372,321. COMPASS Pathways has a twelve month low of $3.16 and a twelve month high of $12.75. The stock's 50 day moving average is $4.10 and its 200-day moving average is $5.43. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The stock has a market capitalization of $312.68 million, a PE ratio of -2.08 and a beta of 2.28.

Institutional Trading of COMPASS Pathways

Several institutional investors have recently bought and sold shares of the stock. Integral Health Asset Management LLC bought a new position in shares of COMPASS Pathways during the fourth quarter valued at $756,000. Cubist Systematic Strategies LLC increased its holdings in shares of COMPASS Pathways by 205.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 126,636 shares of the company's stock worth $479,000 after buying an additional 85,213 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in COMPASS Pathways during the 4th quarter valued at $2,458,000. Jane Street Group LLC raised its position in COMPASS Pathways by 72.7% in the 4th quarter. Jane Street Group LLC now owns 51,815 shares of the company's stock valued at $196,000 after purchasing an additional 21,815 shares during the last quarter. Finally, AdvisorShares Investments LLC boosted its stake in COMPASS Pathways by 51.8% in the fourth quarter. AdvisorShares Investments LLC now owns 66,602 shares of the company's stock worth $252,000 after purchasing an additional 22,720 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.